Physician profile
Andrew E Pitt
NPI 1275699118
$8,662.47
in general payments reported to CMS, 2019-2025
26 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $553 · 2021: $1,015 · 2022: $995 · 2023: $1,502 · 2024: $2,018 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,561 · Education: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,560.68 |
| Education | $341.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,357.37 | 2019-2025 | |
| Janssen Biotech, INC. | $1,848.93 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $1,262.72 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $481.85 | 2019-2025 | |
| Pfizer INC. | $455.00 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $358.65 | 2019-2025 | Dupixent |
| Amgen INC. | $351.32 | 2020-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $234.19 | 2022-2024 | Sotyktu |
| Ucb, INC. | $218.01 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $203.31 | 2019-2023 | Ilumya |
| Helsinn Therapeutics (U.S.), INC. | $130.94 | 2019-2021 | |
| Dermira, INC. | $96.46 | 2020-2021 | |
| Genzyme Corporation | $96.10 | 2021-2025 | |
| Incyte Corporation | $90.86 | 2022-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $75.22 | 2024-2025 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $70.85 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.49 | 2019-2022 | |
| Galderma Laboratories, L.P. | $62.71 | 2021-2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $45.11 | 2019 | |
| Biofrontera INC. | $39.57 | 2019 | |
| Medtronic, INC. | $23.25 | 2022 | |
| Leo Pharma INC. | $20.11 | 2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.82 | 2022 | |
| Smith+Nephew, INC. | $19.48 | 2025 | Grafix Pl |
| Almirall LLC | $18.04 | 2019 | |
| Vyne Pharmaceuticals INC. | $15.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.